Results 61 to 70 of about 9,786 (244)

PERBEDAAN KADAR SGOT, SGPT DAN GAMMA GT PADA PASIEN TALASEMIA BETA MAYOR DENGAN KELASI BESI DEFERASIROX DAN DEFERIPRONE [PDF]

, 2016
Background: Iron accumulation in liver in patient with major thalassemia which has already having repeated transfution could cause liver disfuntion. Iron chelation is understood to be needed to reduce the dysfunction of the liver.
Abdussalam, Reza, Harsono, Ganung, Soebagyo, Bambang   +2 more
core  

A case of depression with psychotic features associated with hemoglobin Manukau mutation

Psychiatry and Clinical Neurosciences Reports, Volume 4, Issue 3, September 2025.
Abstract Background It is pertinent to investigate organic possibilities in acute presentation of mental illness. Iron‐deficiency anemia has long been established to cause symptoms of major depressive disorder. The association between depression and hemolytic anemia and hemochromatosis is less understood.
Zhonghao Zhang, Alana Greenberg, Linda Rose, Thilini Jayasooriya, Naveen Thomas, Soumitra Das   +5 more
wiley   +1 more source

Deferasirox Derivatives: Ligands for the Lanthanide Series

Journal of the American Chemical Society, 2023
Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A
Daniel N. Mangel, Gabriel J. Juarez, Stephanie H. Carpenter, Axel Steinbrueck, Vincent M. Lynch, Jian Yang, Adam C. Sedgwick, Aaron Tondreau, Jonathan L. Sessler   +8 more
openaire   +4 more sources

Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells [PDF]

, 2016
Background Overcoming resistance to treatment is an essential issue in many cancers including glioblastoma (GBM), the deadliest primary tumor of the central nervous system.
C. Guillet, C. Legendre, E. Garcion, S. Avril   +3 more
core   +5 more sources

Deferasirox – a rarer cause of Fanconi syndrome [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2019
Deferasirox is a recently approved iron chelator and is widely used to treat iron overload in transfusion-dependent patients. Its once-daily dosing and oral route of administration have made it an appealing alternative to deferoxamine. Recent case studies have brought to light its potential to cause damage to the proximal convoluted tubule resulting in
Iman Khan, Janki Patel, Mustafa Noor Muhammad   +2 more
openaire   +4 more sources

The Role of Ferroptosis in Women's Health and Diseases

MedComm, Volume 6, Issue 8, August 2025.
At present, there are many common women's diseases, such as preeclampsia (PE), ovarian cancer, and cervical cancer, endangering women's health. These diseases all over the world are characterized by high morbidity and mortality. In the past decade, ferroptosis, a unique pattern of programmed cell death primarily driven by iron‐dependent phospholipid ...
Qiang Xu, Chongying Zhu, Lin Li, Jiayong Li, Zihao An, Chao Tang   +5 more
wiley   +1 more source

Hypersensitivity Myocarditis Following Deferasirox Administration

Circulation: Cardiovascular Imaging, 2022
We describe a case of A 73-year-old woman, receiving regular blood transfusion for 2 years as affected by myelodysplasia and under treatment with deferasirox (14 mg/kg daily; 2 tablets of 360 mg/die) in the last 2 months due to the registration of high levels of ferritin (1000 μg/L) was admitted because of acute heart failure. She was on treatment only
Frustaci, Andrea, Verardo, Romina, Labbadia, Giancarlo, Menafra, Vito, Galea, Nicola, Antonio Russo, Matteo   +5 more
openaire   +3 more sources

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. [PDF]

, 2013
OBJECTIVE: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010.
Armstrong, Edward P, Ballas, Samir K., Sasane, Medha, Skrepnek, Grant H, Snodgrass, Susan M   +4 more
core   +1 more source

Growing Interest in Pharmaceutical Cocrystals: A Comprehensive Review of Applications and Trends

ChemistrySelect, Volume 10, Issue 30, August 8, 2025.
Cocrystallization of an Active Pharmaceutical Ingredient (API) with a suitable coformer enables the development of multicomponent crystalline systems through green, cost‐effective methods. These cocrystals can enhance key physicochemical and biopharmaceutical properties. Abstract The synthesis of cocrystals stands as a promising and compelling strategy
Sandra Barbosa Neder Agostini, Bruno Arantes Borges, Magali Benjamim de Araújo, Rudy Bonfilio   +3 more
wiley   +1 more source

Deferasirox for managing iron overload in people with thalassaemia [PDF]

Cochrane Database of Systematic Reviews, 2017
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective; however, a review of the ...
Bollig, Claudia, Schell, Lisa K., Rücker, Gerta, Allert, Roman, Motschall, Edith, Niemeyer, Charlotte Marie, Bassler, Dirk, Meerpohl, Jörg J.   +7 more
openaire   +5 more sources